Lucentis recommended for Treatment of Age-Related Macular Degeneration

The National Institute for Health and Clinical Excellence (NICE) has recommended that Lucentis is approved to treat people with visual impairment due to macular oedema within the NHS in England and Wales.

The Institute’s Final Appraisal Determination (FAD) recommends the drug, which is also known as ranibizumab, for the treatment of people with macular oedema as a result of a blockage of the central retinal vein (CRVO), as well as those with a blockage to one of the branches of the central vein (BRVO) when laser treatment is not beneficial or appropriate.
 
This news is the third positive recommendation for Lucentis over the last few months and follows both NICE’s and the Scottish Medicines Consortium’s (SMC) approval of the drug for use in patients with vision impairment due to diabetic macular oedema
 
Welcoming the news, Ian Pearce, consultant ophthalmologist and vitreo-retinal surgeon at St Paul’s Eye Unit in the Royal Liverpool Hospital, said: “The decision by NICE to recommend ranibizumab for the treatment of CRVO and BRVO is great news for people with these conditions. The impact of the visual impairment we so often see in people with RVO can have a significant impact on a person’s quality of life.
 
“Ranibizumab has been used to great success in the treatment of wet AMD for a number of years. It is an established and well-tolerated treatment which when used to treat RVO can lead to rapid and significant gains in vision. The impact of this cannot be underestimated as it can make the difference in a person’s ability to carry out everyday tasks such as reading and driving. I hope that following publication of final NICE guidance we see its rapid implementation across the NHS.”
0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply